Company Overview

Company name: NEMUS Bioscience (PINX: NMUS)
Description: Developer of cannabinoid product candidates designed to focus on discovering, developing and commercializing cannabinoid-based therapeutics. The company’s cannabinoid product candidates exert multiple effects on the human body, including immune response, nervous system function and repair, gastrointestinal maintenance and motility, enabling physicians to treat many disorders or alleviating disease-associated symptoms.
Year founded: 2012
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
Website: www.nemusbioscience.com
Employees: 3
City: Long Beach
State: California
Country: United States
Region: Americas

Financial Highlights

Start up capital raised (USD Million): 28.87
Business status: Generating Revenue
Ownership: Publicly Held
Exchange: PINX
Ticker: NMUS
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million) -13.60
Enterprise value: 38.13
Earnings before interest, tax, depreciation and amortization (EBITDA): -13.60
Fiscal period: TTM 3Q2018
Financing Status: The company (OTCQB: NMUS) received $20 million of development capital from Schneider Brothers on May 4, 2017, through a private placement. The financing will help the company meet patent and licensing obligations, advance the methicillin-resistant Staphylococcus aureus (MRSA) and chemotherapy-induced nausea and vomiting (CINV) programs and help initiate the needed steps to industrial-scale-up manufacturing of its analogue of CBD. Previously, the company received $1.2 million of development capital from undisclosed investors on January 10, 2017 through a private placement.
Number of active investors:
Profile last updated: 09-Oct-2018
Last known valuation:
Last known valuation date: